People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Icosavax, Inc. | — | Biotechnology | Series C | $129.7M | $3.1B | 2021 |
Cassia A. Cearley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cassia A. Cearley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tadataka Yamada, M.D. | 1 | 2 |
| Peter A. Kolchinsky | 1 | 2 |
| Eric A. Moessinger | 1 | 2 |
| Adam K. Simpson | 1 | 2 |
| Terry A Gould | 1 | 2 |
| Jason A. Hafler | 1 | 1 |
| Niranjan A. Kanesa-thasan | 1 | 1 |
| Douglas A. Holtzman | 1 | 1 |
| Charles A. Richardson | 1 | 1 |
| Mark A. McDade | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.